RESEARCH LIBRARYBIBLIOTECA DE INVESTIGACIÓNPRIMARY SOURCES · CONTEXT · CHANGELOGFUENTES PRIMARIAS · CONTEXTO · ACTUALIZACIONES
Original PEPTORA notes for compounds people most often compare. Each brief separates the mechanism, the question being studied, the evidence setting and the limits of inference.
Mechanism. A triple agonist studied across GLP‑1, GIP and glucagon receptors.
Research question. How multi-incretin signalling changes weight and metabolic endpoints in defined clinical populations.
Compare. Tirzepatide, Cagrilintide and Mazdutide are related metabolic conversations, not interchangeable molecules.
Boundary. A phase‑2 obesity trial is clinical evidence in a defined population; it is not a general biohacking outcome.
PRIMARY STUDY ↗Mechanism. A mitochondrial-derived peptide studied in metabolic and exercise-related signalling.
Research question. How circulating and tissue-level MOTS‑c relates to acute exercise and metabolic state.
Compare. NAD+ and SS‑31 concern cellular-energy conversations through different biology.
Boundary. Human observations of endogenous MOTS‑c do not demonstrate a performance result from a product.
PRIMARY STUDY ↗Mechanism. An ACTH(4–10) analogue investigated in neurotrophic and BDNF/TrkB-related research.
Research question. Whether specific neural signalling changes occur in experimental systems.
Compare. Selank belongs to stress/GABA conversations; it is not the same cognitive profile.
Boundary. Rodent BDNF findings do not establish a personal focus or neuroplasticity outcome.
PRIMARY STUDY ↗Mechanism. A GHRH analogue considered in endocrine and visceral-adiposity discussions.
Research question. Its evidence must be read within the labelled population and indication.
Compare. CJC no DAC and Ipamorelin are different GH-axis research references.
Boundary. Regulatory context does not support generic body-composition claims.
FDA LABEL ↗Mechanism. Tissue-response, actin-dynamics and dermal-signalling conversations span distinct components.
Research question. BPC‑157, TB‑500, GHK‑Cu and KPV must be read separately before a blend is discussed.
Compare. GLOW is BPC‑157 + TB‑500 + GHK‑Cu; KLOW adds KPV.
Boundary. Component literature cannot be added together as clinical evidence for a blend.
PRIMARY-LITERATURE INDEX ↗Mechanism. A central cellular redox cofactor, not a peptide.
Research question. Which redox, metabolic and mitochondrial measures change in a given study context.
Compare. MOTS‑c and SS‑31 intersect with cellular-energy conversations but do not share one mechanism.
Boundary. Central biological importance is not proof of a longevity outcome from any formulation.
PRIMARY-LITERATURE INDEX ↗PEPTORA LIBRARYBIBLIOTECA PEPTORAORIGINAL EDITORIAL ROUTESRUTAS EDITORIALES ORIGINALES
How to separate receptor activity from metabolic outcomes.Cómo distinguir actividad de receptores y resultados metabólicos.
02How to read Semax, Selank and neurotrophic claims.Cómo leer la investigación sobre Semax, Selank y señalización neural.
03Why mechanisms and blend claims need separate evidence.Por qué mecanismos y combinaciones requieren evidencia separada.
04MOTS‑c, NAD+ and cellular-signalling context.MOTS-c, NAD+ y el contexto de señalización celular.
SCIENTIFIC CHANGELOGHISTORIAL EDITORIALREVIEW STATUSESTADO DE REVISIÓN